mRNA Cancer Vaccine (BNT116)

Type: vaccine

Status: Investigational (UK/Germany trial sites)

Developer: BioNTech

Breakthrough Summary

No summary available.

Mechanism of Action

mRNA encoding NSCLC tumor antigens to prime immune response

Year: 2025-2026